Blood pressure and lipid management fall far short in persons with type 2 diabetes: results from the DIAB-CORE Consortium including six German population-based studies

Cardiovascular Diabetology

Volumn 11, Issue , 2012, Pages

  Rückert, Ina Maria ^a   Schunk, Michaela ^a   Holle, Rolf ^a   Schipf, Sabine ^b   Völzke, Henry ^b   Kluttig, Alexander ^c   Greiser, Karin Halina ^c,d   Berger, Klaus ^e   Müller, Grit ^e   Ellert, Ute ^f   Neuhauser, Hannelore ^f   Rathmann, Wolfgang ^g   Tamayo, Teresa ^g   Moebus, Susanne ^h   Andrich, Silke ^h   Meisinger, Christa ^a,i  

^a INSTITUTE OF EPIDEMIOLOGY   (Germany)

^b UNIVERSITY OF GREIFSWALD   (Germany)

^c MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^d GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^e UNIVERSITY OF MÜNSTER   (Germany)

^f ROBERT KOCH INSTITUTE   (Germany)

^g HEINRICH HEINE UNIVERSITY   (Germany)

^h UNIVERSITY HOSPITAL ESSEN   (Germany)

ⁱ KLINIKUM AUGSBURG   (Germany)

Author keywords

Adherence to guidelines; Dyslipidemia; Hypertension; Pharmacological treatment; Type 2 Diabetes

Indexed keywords

ANGIOTENSIN DERIVATIVE; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHOLESTEROL; DIURETIC AGENT; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; PERIPHERAL VASODILATING AGENT;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD GLUCOSE MONITORING; BLOOD PRESSURE REGULATION; CHOLESTEROL BLOOD LEVEL; COMORBIDITY; DYSLIPIDEMIA; FEMALE; GERMANY; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; LIPID ANALYSIS; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; RISK FACTOR;

AGED; ANTIHYPERTENSIVE AGENTS; BIOLOGICAL MARKERS; BLOOD PRESSURE; CHI-SQUARE DISTRIBUTION; COMORBIDITY; DIABETES MELLITUS, TYPE 2; DYSLIPIDEMIAS; FEMALE; GERMANY; GUIDELINE ADHERENCE; HUMANS; HYPERTENSION; HYPOLIPIDEMIC AGENTS; LIPIDS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES AS TOPIC; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME;

EID: 84860611914     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-11-50     Document Type: Article

References (54)

1. Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA 2002, 287:2570-2581. 10.1001/jama.287.19.2570, 12020339.
2. Brezel RG, Landgraf R, Janka HU, Mann J, Merker L. DDG Praxis Leitlinie: hypertonie beim diabetes mellitus. Diabetologie 2007, 2:157-158.
3. Sowers JR, Epstein M, Frohlich ED. Diabetes, hypertension, and cardiovascular disease: an update. Hypertension 2001, 37:1053-1059. 10.1161/01.HYP.37.4.1053, 11304502.
4. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998, 339:229-234. 10.1056/NEJM199807233390404, 9673301.
5. Chukwuma C, Tuomilehto J. Diabetes and the risk of stroke. J Diabetes Complications 1993, 7:250-262. 10.1016/S0002-9610(05)80253-3, 8219369.
6. Hedblad B, Nilsson P, Engstrom G, Berglund G, Janzon L. Insulin resistance in non-diabetic subjects is associated with increased incidence of myocardial infarction and death. Diabet Med 2002, 19:470-475. 10.1046/j.1464-5491.2002.00719.x, 12060058.
7. Verhagen SN, Wassink AM, van der Graaf Y, Gorter PM, Visseren FL. Insulin resistance increases the occurrence of new cardiovascular events in patients with manifest arterial disease without known diabetes. the SMART study. Cardiovasc Diabetol 2011, 10:100. 10.1186/1475-2840-10-100, 3268731, 22098712.
8. American Diabetes Association Standards of medical care in diabetes--2011. Diabetes Care 2011, 34(Suppl 1):S11-S61. 3006050, 21193625, American Diabetes Association.
9. Bischoff B, Silber S, Richartz BM, Pieper L, Klotsche J, Wittchen HU. Inadequate medical treatment of patients with coronary artery disease by primary care physicians in Germany. Clin Res Cardiol 2006, 95:405-412. 10.1007/s00392-006-0399-2, 16799879.
10. Sharma AM, Wittchen HU, Kirch W, Pittrow D, Ritz E, Goke B, Lehnert H, Tschope D, Krause P, Hofler M, et al. High prevalence and poor control of hypertension in primary care: cross-sectional study. J Hypertens 2004, 22:479-486. 10.1097/00004872-200403000-00009, 15076152.
11. Steckelings UM, Stoppelhaar M, Sharma AM, Wittchen HU, Krause P, Kupper B, Kirch W, Pittrow D, Ritz E, Goke B, et al. HYDRA: possible determinants of unsatisfactory hypertension control in German primary care patients. Blood Press 2004, 13:80-88. 10.1080/08037050310030982, 15182110.
12. Berthold HK, Bestehorn KP, Krone W, Gouni-Berthold I. Atherosclerotic disease location and disparities in the control and treatment of cardiovascular risk factors in patients with Type 2 diabetes. Diabet Med 2010, 27:303-308. 10.1111/j.1464-5491.2010.02952.x, 20536493.
13. Brown LC, Johnson JA, Majumdar SR, Tsuyuki RT, McAlister FA. Evidence of suboptimal management of cardiovascular risk in patients with type 2 diabetes mellitus and symptomatic atherosclerosis. CMAJ 2004, 171:1189-1192. 10.1503/cmaj.1031965, 524949, 15534311.
14. Godley PJ, Maue SK, Farrelly EW, Frech F. The need for improved medical management of patients with concomitant hypertension and type 2 diabetes mellitus. Am J Manag Care 2005, 11:206-210.
15. Icks A, Rathmann W, Haastert B, Mielck A, Holle R, Lowel H, Giani G, Meisinger C. Quality of care and extent of complications in a population-based sample of patients with type 2 diabetes mellitus. The KORA Survey 2000]. Dtsch Med Wochenschr 2006, 131:73-78. 10.1055/s-2006-924927, 16418944.
16. Schunk M, Stark R, Reitmeir P, Rathmann W, Meisinger C, Holle R. Improvements in type 2 diabetes care? Pooled analysis of survey data in southern Germany (KORA) from 1999-2008. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2011, 54:1187-1196. 10.1007/s00103-011-1364-4, 22015791.
17. Raum E, Lietzau S, Stegmaier C, Brenner H, Rothenbacher D. For the majority of patients with diabetes blood pressure and lipid management is not in line with recommendations. Results from a large population-based cohort in Germany. Pharmacoepidemiol Drug Saf 2008, 17:485-494. 10.1002/pds.1589, 18383562.
18. Wens J, Gerard R, Vandenberghe H. Optimizing diabetes care regarding cardiovascular targets at general practice level: Direct@GP. Prim Care Diabetes 2011, 5:19-24. 10.1016/j.pcd.2010.09.006, 21030327.
19. Vennemann MM, Hummel T, Berger K. The association between smoking and smell and taste impairment in the general population. J Neurol 2008, 255:1121-1126. 10.1007/s00415-008-0807-9, 18677645.
20. Rathmann W, Haastert B, Icks A, Lowel H, Meisinger C, Holle R, Giani G. High prevalence of undiagnosed diabetes mellitus in Southern Germany: target populations for efficient screening. The KORA survey 2000. Diabetologia 2003, 46:182-189.
21. Greiser KH, Kluttig A, Schumann B, Kors JA, Swenne CA, Kuss O, Werdan K, Haerting J. Cardiovascular disease, risk factors and heart rate variability in the elderly general population: design and objectives of the CARdiovascular disease, Living and Ageing in Halle (CARLA) Study. BMC Cardiovasc Disord 2005, 5:33. 10.1186/1471-2261-5-33, 1299322, 16283930.
22. Völzke H, Alte D, Schmidt CO, Radke D, Lorbeer R, Friedrich N, Aumann N, Lau K, Piontek M, Born G, et al. Cohort profile: the study of health in Pomerania. Int J Epidemiol 2011, 40:294-307. 10.1093/ije/dyp394, 20167617.
23. Bellach BM, Knopf H, Thefeld W. The German Health Survey. 1997/98. Gesundheitswesen 1998, 60(Suppl 2):S59-S68.
24. Neuhauser HK, Ellert U, Kurth BM. A comparison of Framingham and SCORE-based cardiovascular risk estimates in participants of the German National Health Interview and Examination Survey 1998. Eur J Cardiovasc Prev Rehabil 2005, 12:442-450. 10.1097/01.hjr.0000183909.52118.9f, 16210930.
25. Schmermund A, Mohlenkamp S, Stang A, Gronemeyer D, Seibel R, Hirche H, Mann K, Siffert W, Lauterbach K, Siegrist J, et al. Assessment of clinically silent atherosclerotic disease and established and novel risk factors for predicting myocardial infarction and cardiac death in healthy middle-aged subjects: rationale and design of the Heinz Nixdorf RECALL Study. Risk Factors, Evaluation of Coronary Calcium and Lifestyle. Am Heart J 2002, 144:212-218. 10.1067/mhj.2002.123579, 12177636.
26. Meisinger C, Heier M, Völzke H, Lowel H, Mitusch R, Hense HW, Ludemann J. Regional disparities of hypertension prevalence and management within Germany. J Hypertens 2006, 24:293-299. 10.1097/01.hjh.0000200508.10324.8e, 16508575.
27. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, Jones DW, Materson BJ, Oparil S, Wright JT, Roccella EJ. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003, 42:1206-1252. 10.1161/01.HYP.0000107251.49515.c2, 14656957.
28. Whitworth JA. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens 2003, 21:1983-1992.
29. Williams B, Poulter NR, Brown MJ, Davis M, McInnes GT, Potter JF, Sever PS, Thom SM. British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary. BMJ 2004, 328:634-640. 10.1136/bmj.328.7440.634, 381142, 15016698.
30. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, Grassi G, Heagerty AM, Kjeldsen SE, Laurent S, et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007, 25:1105-1187. 10.1097/HJH.0b013e3281fc975a, 17563527.
31. Rosendorff C, Black HR, Cannon CP, Gersh BJ, Gore J, Izzo JL, Kaplan NM, O'Connor CM, O'Gara PT, Oparil S. Treatment of hypertension in the prevention and management of ischemic heart disease: a scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention. Circulation 2007, 115:2761-2788. 10.1161/CIRCULATIONAHA.107.183885, 17502569.
32. Glandt M, Bloomgarden ZT. Hypertension in diabetes: treatment considerations. J Clin Hypertens (Greenwich) 2011, 13:314-318.
33. Bergert FW, Braun M, Ehrenthal K, Feßler J, Gross J. Hausärztliche Leitlinie Hypertonie. Therapie der Hypertonie. Hausärztliche Pharmakotherapie 2008, Version 3.09.
34. Meisinger C, Loewel H, Mraz W, Koenig W. Prognostic value of apolipoprotein B and A-I in the prediction of myocardial infarction in middle-aged men and women: results from the MONICA/KORA Augsburg cohort study. Eur Heart J 2005, 26:271-278.
35. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001, 285:2486-2497. 10.1001/jama.285.19.2486, 11368702.
36. Kinosian B, Glick H, Garland G. Cholesterol and coronary heart disease: predicting risks by levels and ratios. Ann Intern Med 1994, 121:641-647.
37. Rahn KH. Leitliniengerechte Differenzialtherapie der Hypertonie. Internist 2009, 50:433-441. 10.1007/s00108-008-2292-8, 19305959.
38. Charpentier G, Genes N, Vaur L, Amar J, Clerson P, Cambou JP, Gueret P. Control of diabetes and cardiovascular risk factors in patients with type 2 diabetes: a nationwide French survey. Diabetes Metab 2003, 29:152-158. 10.1016/S1262-3636(07)70022-8, 12746636.
39. Deguzman PB, Akosah KO, Simpson AG, Barbieri KE, Megginson GC, Goldberg RI, Beller GA. Sub-optimal achievement of guideline-derived lipid goals in management of diabetic patients with atherosclerotic cardiovascular disease, despite high use of evidence-based therapies. Diab Vasc Dis Res 2012, 9:138-145. 10.1177/1479164111431471, 22234950.
40. Kuznik A, Mardekian J. Trends in utilization of lipid- and blood pressure-lowering agents and goal attainment among the U.S. diabetic population, 1999-2008. Cardiovasc Diabetol 2011, 10:31. 10.1186/1475-2840-10-31, 3098774, 21496321.
41. Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80%. BMJ 2003, 326:1419. 10.1136/bmj.326.7404.1419, 162259, 12829553.
42. Borgermans LA, Goderis G, Ouwens M, Wens J, Heyrman J, Grol RP. Diversity in diabetes care programmes and views on high quality diabetes care: are we in need of a standardized framework?. Int J Integr Care 2008, 8:e07. 2387191, 18493592.
43. Hanefeld M, Metzler W, Kohler C, Schaper F. Metabolic syndrome: "common soil" for diabetes and atherosclerosis. Novel approaches to an integrated therapy. Herz 2006, 31:246-254. quiz 255, 10.1007/s00059-006-2798-6, 16770562.
44. Mogensen CE. Drug treatment for hypertensive patients in special situations: diabetes and hypertension. Clin Exp Hypertens 1999, 21:895-906. 10.3109/10641969909061018, 10423111.
45. Sawicki PT, Siebenhofer A. Betablocker treatment in diabetes mellitus. J Intern Med 2001, 250:11-17. 10.1046/j.1365-2796.2001.00829.x, 11454137.
46. Cushman WC, Evans GW, Byington RP, Goff DC, Grimm RH, Cutler JA, Simons-Morton DG, Basile JN, Corson MA, Probstfield JL, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 2010, 362:1575-1585.
47. Ginsberg HN, Elam MB, Lovato LC, Crouse JR, Leiter LA, Linz P, Friedewald WT, Buse JB, Gerstein HC, Probstfield J, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010, 362:1563-1574. 2879499, 20228404.
48. Lewis SJ. Lipid-lowering therapy: who can benefit?. Vasc Health Risk Manag 2011, 7:525-534. 3166192, 21915170.
49. Culver AL, Ockene IS, Balasubramanian R, Olendzki BC, Sepavich DM, Wactawski-Wende J, Manson JE, Qiao Y, Liu S, Merriam PA, et al. Statin Use and Risk of Diabetes Mellitus in Postmenopausal Women in the Women's Health Initiative. Arch Intern Med 2012, 172:144-152. 10.1001/archinternmed.2011.625, 22231607.
50. Preiss D, Seshasai SR, Welsh P, Murphy SA, Ho JE, Waters DD, DeMicco DA, Barter P, Cannon CP, Sabatine MS, et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA 2011, 305:2556-2564. 10.1001/jama.2011.860, 21693744.
51. Dusing R. Overcoming barriers to effective blood pressure control in patients with hypertension. Curr Med Res Opin 2006, 22:1545-1553. 10.1185/030079906X120995, 16870079.
52. Bailey CJ, Kodack M. Patient adherence to medication requirements for therapy of type 2 diabetes. Int J Clin Pract 2011, 65:314-322. 10.1111/j.1742-1241.2010.02544.x, 21314869.
53. Stark RG, Schunk MV, Meisinger C, Rathmann W, Leidl R, Holle R. Medical care of type 2 diabetes in German disease management programmes: a population-based evaluation. Diabetes Metab Res Rev 2011, 27:383-391. 10.1002/dmrr.1186, 21308948.
54. Asimakopoulou KG, Skinner TC, Spimpolo J, Marsh S, Fox C. Unrealistic pessimism about risk of coronary heart disease and stroke in patients with type 2 diabetes. Patient Educ Couns 2008, 71:95-101. 10.1016/j.pec.2007.12.007, 18242931.